Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
STX-478 in advanced solid tumors
2023-504807-94-00Phase 2Authorised
- Sponsor
- Scorpion Therapeutics
- Start
- Dec 2023
- Modality
- Small Molecules
- Countries
- 10
01
Overview
Phase 2, open-label trial of tersolisib in breast cancer, gynecological cancer, head and neck squamous cell carcinoma (HNSCC) and 1 more (2 arms), sponsored by Scorpion Therapeutics. Planned start Dec 2023; status: authorised.
02
Drugs
tersolisib
03
Conditions
breast cancergynecological cancerhead and neck squamous cell carcinoma (HNSCC)Nonhematologic neoplasms
Beyond the preview
Go deeper on 2023-504807-94-00.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2023-504807-94-00.